What Is Kisspeptin?
Kisspeptin is a reproductive-signaling peptide that acts upstream of LH and other reproductive hormones. It plays an important role in reproductive signaling and has been investigated in fertility, hypothalamic amenorrhea and sexual-response research.
Main Forms
Kisspeptin-10 (KP-10) and Kisspeptin-54 (KP-54).
Primary Function
Regulation of reproductive hormone signaling.
Hormonal Pathways
Primarily associated with LH and FSH signaling.
Research Areas
Fertility, hypothalamic amenorrhea and sexual-response research.
Evidence Status
Human studies exist in specific reproductive contexts, but evidence for general testosterone optimization remains limited.
Important Peptide Distinction
Kisspeptin-10 and Kisspeptin-54 are different peptide forms. Their research findings, administration contexts and formulation characteristics should not be treated as interchangeable.
Reported Kisspeptin Schedules
The following information summarizes community-reported schedules and separate clinical research examples. These figures are not established personal dosing recommendations.
SC example
Per administration
Frequency
Daily total
Reported cycle
Community SC — Lower Range
50–100 mcg
Once daily
50–100 mcg/day
Not specified in source
Community SC — Higher Range
100–200 mcg
Once daily; an alternative report describes 100 mcg twice daily.
100–200 mcg/day; the alternative twice-daily example totals 200 mcg/day.
Not specified in source
Clinical Research Examples
1.6–12.8 nmol/kg (Kisspeptin-54 IVF study boluses)
IVF studies: single SC boluses. Amenorrhea study: 6.4 nmol/kg twice weekly. HSDD experiments: 1 nmol/kg/hour IV for 75 minutes.
Not directly comparable across different clinical study designs.
Study-specific schedules; no universal cycle established.
Community SC — Lower Range
Per administration
50–100 mcg
Daily total
50–100 mcg/day
Reported cycle
Not specified in source
Community SC — Higher Range
Per administration
100–200 mcg
Frequency
Once daily; an alternative report describes 100 mcg twice daily.
Daily total
100–200 mcg/day; the alternative twice-daily example totals 200 mcg/day.
Reported cycle
Not specified in source
Clinical Research Examples
Per administration
1.6–12.8 nmol/kg (Kisspeptin-54 IVF study boluses)
Frequency
IVF studies: single SC boluses. Amenorrhea study: 6.4 nmol/kg twice weekly. HSDD experiments: 1 nmol/kg/hour IV for 75 minutes.
Daily total
Not directly comparable across different clinical study designs.
Reported cycle
Study-specific schedules; no universal cycle established.
Community-reported schedules and clinical study protocols represent different evidence contexts. Peptide form, route, measurement units and study purpose must be considered separately.
Continuous Stimulation and Desensitization
Continuous Kisspeptin stimulation may reduce the hormonal response through tachyphylaxis or desensitization. A universal dose-escalation schedule or testosterone-support protocol has not been established.
Kisspeptin Safety Considerations
Kisspeptin influences reproductive hormone signaling. Its effects depend on peptide form, exposure pattern and reproductive context. Human clinical interpretation is important when evaluating hormonal or fertility-related research.
Reported Safety Considerations
Kisspeptin Storage Guidelines
Storage Conditions
Cold storage and protection from light are discussed in the source. Exact requirements depend on the formulation.
Peptide Forms
Kisspeptin-10 and Kisspeptin-54 have different formulation and handling considerations.
Mixed Product Stability
A universal mixed-product stability period is not established. Product-specific stability documentation is required.
Product Verification
Verify peptide identity, formulation, storage requirements and manufacturer documentation before interpreting product information.
Kisspeptin Concentration Calculator
Explore the mathematical relationship between peptide amount, assumed final volume and concentration. These examples are for educational calculations only.
Amount (mg)
Final volume (mL)
Concentration (mg/mL)
Per 1 U (mcg)
Per 10 U (mcg)
Concentration (mg/mL)
6.667
U refers to a U-100 volume marking, where 1 U = 0.01 mL. Additional examples: 10 mg in 2 mL = 5 mg/mL, 50 mcg per 1 U and 500 mcg per 10 U; 10 mg in 2.5 mL = 4 mg/mL, 40 mcg per 1 U and 400 mcg per 10 U. These are mathematical examples only, not preparation or administration instructions. For blends, total mass must not be confused with the amount of each individual ingredient.
Kisspeptin Research Findings
Human research has investigated Kisspeptin in specific reproductive and sexual-response settings. These findings do not establish broad benefits for testosterone optimization or post-cycle therapy.
IVF Research
Kisspeptin-54 has been investigated in IVF-related research using single subcutaneous bolus study designs. These findings belong to specific fertility-treatment contexts.
Hypothalamic Amenorrhea
A human amenorrhea study examined Kisspeptin using a reported 6.4 nmol/kg schedule twice weekly. This does not establish a general-purpose hormonal treatment protocol.
Sexual-Response Research
HSDD-related experiments investigated intravenous Kisspeptin exposure at 1 nmol/kg/hour for 75 minutes. These experimental findings do not establish general testosterone or sexual-performance benefits.
Research and Regulatory Status
Evidence and Approval Limitations
Kisspeptin research includes human fertility, hypothalamic and sexual-response experiments. The source does not establish a general approved injection protocol for testosterone optimization or post-cycle therapy. Research findings should not be interpreted as proof of safety or effectiveness for unapproved uses.
This page is for educational and research-information purposes only. It is not medical advice, a prescription or a recommendation to use Kisspeptin. Consult a qualified healthcare professional for individual medical or reproductive-health decisions.
